Guignon Anne-Maëlle, Mallaret Michel P, Jouk Pierre Simon
Centre Régional de Pharmacovigilance, Centre Hospitalier Universitaire de Grenoble, Grenoble, France.
Ann Pharmacother. 2003 Jun;37(6):829-31. doi: 10.1345/aph.1C368.
To report a case of gastroschisis in a newborn secondary to carbimazole exposure in utero.
A 25-year-old white woman was treated for Graves disease with carbimazole throughout pregnancy. A boy was born prematurely by vaginal delivery, with a gastroschisis without associated malformative syndrome. Death occurred in the 25th hour of life after surgical repair.
Carbimazole is completely metabolized to methimazole after absorption. Carbimazole or methimazole intake during pregnancy has been associated with an increased incidence of scalp aplasia. Abdominal wall defects secondary to carbimazole or methimazole exposure in utero seem to be a rare occurrence. However, other cases of abdominal wall defects have been reported in 4 newborns, 2 of them associated with scalp aplasia. An objective causality assessment revealed that the relationship between the gastroschisis and the exposure to carbimazole in utero was possible.
It is important to emphasize the possible risk of abdominal wall defects in newborns to pregnant women taking carbimazole or methimazole.
报告1例因孕期接触卡比马唑导致新生儿腹裂的病例。
一名25岁白人女性在整个孕期都使用卡比马唑治疗格雷夫斯病。一名男婴经阴道早产，患有腹裂，无相关畸形综合征。手术修复后，该男婴在出生后第25小时死亡。
卡比马唑吸收后完全代谢为甲巯咪唑。孕期摄入卡比马唑或甲巯咪唑与头皮发育不全的发生率增加有关。宫内接触卡比马唑或甲巯咪唑继发腹壁缺损似乎很少见。然而，另有4例新生儿腹壁缺损的病例报告，其中2例与头皮发育不全有关。客观的因果关系评估显示，腹裂与宫内接触卡比马唑之间可能存在关联。
对于服用卡比马唑或甲巯咪唑的孕妇，强调新生儿腹壁缺损的潜在风险很重要。
